抗体偶联抗菌药物的研究进展

Research advances of antibody-antibiotic conjugates

细菌耐药性是21世纪全球关注的热点。随着细菌的耐药性问题凸显,作为大分子药物的抗体和疫苗,有望作为抗耐药菌感染的新一代药物。抗体偶联抗菌药物(antiboy-antibiotic conjugates,AAC)是在抗体偶联(抗肿瘤)药物(antibody-drug conjugates,ADC)基础上研发的一类新型抗耐药菌感染的药物,其具有ADC研发的基本理念,但也具有作为抗菌药物的特殊要求。本文就AAC最新进展做一综述。

Bacterial antibiotic resistance is a worldwide challenge in 21st century. As antibiotic resistance becomes more and more serious, macromolecular monoclonal antibodies and the related targeting drugs are expected to be the next generation treatments. Antibody-antibiotic conjugates （AAC）, similar to antibody-drug conjugates （ADC） in tumor therapy, are new types of drugs that are able to treat resistant bacteria infections, taking the advantage of both monoclonal antibody and antibiotics. This paper briefly reviewed the research advances in the development of AACs, as well as the progress in its three components： bacteria targeting monoclonal antibody, the antibiotic payload and the linker which was crucial for the AAC functions.